KalVista Pharmaceuticals Inc (STU:4XC1)
€ 8.8 -0.3 (-3.3%) Market Cap: 442.00 Mil Enterprise Value: 319.24 Mil PE Ratio: 0 PB Ratio: 3.05 GF Score: 30/100

Kalvista Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript

Nov 21, 2019 / 08:00AM GMT
Release Date Price: €11 (+4.76%)
Mitchell Swaroop Kapoor
Jefferies LLC, Research Division - Equity Associate

Hi, everyone. My name is Mitchell Kapoor. I'm an Equity Research Associate at Jefferies. It is my pleasure to welcome the next presenting company, KalVista. And it's my pleasure to welcome Andy Crockett, CEO.

Thomas Andrew Crockett
KalVista Pharmaceuticals, Inc. - CEO & Director

Good morning. Pleased to be with you. My name again is Andy Crockett. I'm the Chief Executive of KalVista. Pleased to be here with you at Jefferies.

Just a reminder that the presentation here does contain forward-looking statements. If I can get the presentation to move, which it's not doing. Here we go. Okay. Forward-looking statements here. Yes. This slide, I don't think is working. Okay.

So just to start off with some company highlights, the covenants that we've been focused on: Discovery and development of small molecule protease inhibitors since our inception. We're creating a portfolio of oral plasma kallikrein inhibitors to treat both hereditary angioedema and diabetic macular

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot